EWHIGH SIGNALFINANCIAL10-K

Edwards Lifesciences experienced a dramatic 74% collapse in net income despite revenue growth, indicating severe operational efficiency deterioration.

The massive profit decline while revenues grew 11.5% suggests significant margin compression and operational challenges that management may be struggling to control. The 16.5% increase in SG&A expenses combined with rising liabilities indicates potential cost structure problems that could persist into future periods.

Comparing 2026-02-25 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

Edwards Lifesciences shows a concerning disconnect between top-line growth and bottom-line performance, with revenue increasing 11.5% to $6.1B while net income collapsed 74% to $1.1B. SG&A expenses surged 16.5% to $2.1B and total liabilities grew 12.3% to $3.4B, while the company reduced share buybacks by 23% to $893M. This financial profile suggests serious operational efficiency issues and potential margin pressures that significantly outweighed revenue gains.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-74.3%
$4.2B→$1.1B

Net income declined 74.3% — review whether driven by operations, interest costs, or non-recurring items.

Share Buybacks
Cash Flow
-22.9%
$1.2B→$893.4M

Buyback activity reduced 22.9% — capital being redeployed elsewhere or cash conservation underway.

Current Liabilities
Balance Sheet
+20.5%
$1.5B→$1.8B

Current liabilities rose 20.5% — increased short-term obligations, watch current ratio.

SG&A Expense
P&L
+16.5%
$1.8B→$2.1B

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Total Liabilities
Balance Sheet
+12.3%
$3.0B→$3.4B

Liabilities increased 12.3% — monitor debt-to-equity ratio and interest coverage.

Revenue
P&L
+11.5%
$5.4B→$6.1B

Revenue growing 11.5% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-28
ADDED
7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 7A.
These statements can sometimes be identified by the use of the forward-looking words such as may, believe, will, expect, project, estimate, should, anticipate, plan, goal, continue, seek, pro forma, forecast, intend, guidance, optimistic, aspire, confident, or other forms of these words or similar words or expressions or the negatives thereof.
Statements regarding past performance, efforts, or results about which inferences or assumptions may be made can also be forward-looking statements and are not indicative of future performance or results; these statements can be identified by the use of words such as preliminary, initial, potential, possible, early feedback, or other forms of these words or similar words or expressions or the negatives thereof.
Unless otherwise indicated or otherwise required by the context, the terms we, our, it, its, Company, Edwards, and Edwards Lifesciences refer to Edwards Lifesciences Corporation and its subsidiaries.
+7 more — sign up free →
REMOVED
7262(b)) by the registered public accounting firm that prepared or issued its audit report .
Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 7A.
These statements can sometimes be identified by the use of the forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "goal," "continue," "seek," "pro forma," "forecast," "intend," "guidance," "optimistic," "aspire," "confident," or other forms of these words or similar words or expressions or the negatives thereof.
Statements regarding past performance, efforts, or results about which inferences or assumptions may be made can also be forward-looking statements and are not indicative of future performance or results; these statements can be identified by the use of words such as "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications," "early feedback," or other forms of these words or similar words or expressions or the negatives thereof.
Unless otherwise indicated or otherwise required by the context, the terms "we," "our," "it," "its," "Company," "Edwards," and "Edwards Lifesciences" refer to Edwards Lifesciences Corporation and its subsidiaries.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →